[6-K] ICICI Bank Limited Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Biotechnology Value Fund and affiliated entities have filed a Schedule 13G disclosing a collective 7.4% passive stake in Nektar Therapeutics (NASDAQ: NKTR). The filing, dated 9 July 2025 with an event date of 1 July 2025, reports aggregate beneficial ownership of 1,276,595 common shares out of 17,301,061 shares outstanding following the company’s recent public offering.

The ownership is spread across multiple Delaware and Cayman-based vehicles: Biotechnology Value Fund (LP) holds 661,758 shares (3.8%), Biotechnology Value Fund II (LP) holds 517,813 shares (3.0%), and Biotechnology Value Trading Fund OS (LP) holds 71,367 shares (<1%). Control is exercised jointly through the general partners BVF GP Holdings LLC and BVF Partners L.P., with Mark N. Lampert signing on behalf of each entity. All shares are held with shared voting and dispositive power; none of the reporting persons claims sole authority.

The filing is made on Form 13G—indicating a passive investment intent rather than an activist position— and includes the customary certification that the securities were not acquired to influence control of the issuer. No other material transactions, derivatives, or lock-up arrangements are disclosed.

Key take-aways for investors: BVF’s aggregated 7.4% stake makes it one of the largest outside shareholders of Nektar, signalling confidence from a specialist biotech investor group. However, because the filing is passive, immediate governance or strategic changes should not be expected.

Positive

• Specialist biotech investor BVF now owns 7.4% of NKTR, adding reputable institutional support.
• Filing is on Schedule 13G, confirming the stake is passive and reducing near-term governance risk.

Negative

• None.

Insights

Securities Analyst

TL;DR – BVF reveals 7.4% passive stake, signalling specialist confidence but no activist intentions.

The 13G shows BVF entities accumulating 1.28 million NKTR shares after the company’s July 2025 equity offering. At 7.4% of outstanding, BVF becomes a significant holder yet stays below the 10% insider threshold and files a passive 13G rather than 13D. For investors, a biotech-focused fund’s sizable position can bolster market sentiment and provide validation of Nektar’s pipeline value. Nevertheless, the passive designation limits expectations for near-term governance influence or catalyst-driven activism. Impact is moderately positive because increased institutional ownership can improve liquidity and support the share price, but there is no direct operational effect.

&nbsp;

UNITED STATES

&nbsp;

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

&nbsp;

FORM 6-K

&nbsp;

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a -16 OR

15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

&nbsp;

For the month of July 2025

Commission File Number: 001-15002

&nbsp;

ICICI Bank Limited

(Translation of registrant&rsquo;s name into English)

&nbsp;

ICICI Bank Towers,
Bandra-Kurla Complex
Mumbai, India 400 051
(Address of principal executive office)

&nbsp;

Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.

&nbsp;

Form 20-F&nbsp;&nbsp;&nbsp;X&nbsp; &nbsp; Form 40-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;

&nbsp;

&nbsp;

&nbsp;

Table of Contents

&nbsp;

Items:

&nbsp;

1. Other news

&nbsp;&nbsp;

&nbsp;

&nbsp;

&nbsp;&nbsp;

&nbsp;

OTHER NEWS

&nbsp;

Subject: Disclosure under Indian Listing Regulations

&nbsp;

IBN&nbsp;

ICICI Bank Limited (the &lsquo;Bank&rsquo;) Report on Form 6-K

&nbsp;

The Bank has made the below announcement to the Indian stock exchanges:

&nbsp;

This is further to our disclosures dated February 12, 2025 and June 27, 2025 with regards to our subsidiary, ICICI Prudential Asset Management Company (the Company).

&nbsp;

The Company has filed a Draft Red Herring Prospectus (DRHP) dated July 8, 2025&nbsp;with Securities and Exchange Board of India, BSE Limited and National Stock Exchange of India Limited for an initial public offering (IPO) comprising of an offer for sale (OFS) of equity shares held by Prudential Corporation Holdings Limited (PCHL) in the Company, representing upto 10% of the equity share capital of the Company. The IPO and the amount of the OFS amount shall be subject to market conditions, requisite approvals and other considerations.

&nbsp;

Additionally, on July 8, 2025 (at 7:11 p.m.), ICICI Bank Limited (the Bank) has entered into an inter-se agreement with PCHL stating its intention to purchase up to 2% of fully-diluted pre-IPO share capital of the Company from PCHL, prior to the consummation of the IPO. This would be subject to finalisation amongst both parties of relevant terms, requisite corporate and statutory approvals as may be required by each of the parties, applicable law and other considerations.

&nbsp;

Pursuant to Regulation 30 read with para A of part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular dated November 11, 2024, the following disclosure are enclosed herewith as Annexure:&nbsp;&nbsp;

&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;

ICICI Bank Limited ICICI Bank Towers Bandra-Kurla Complex Mumbai 400 051, India. Tel.: 022- 4008 8900 Email:companysecretary@icicibank.com Website www.icicibank.com CIN.: L65190GJ1994PLC021012 Regd. Office: ICICI Bank Tower, Near Chakli Circle, Old Padra Road, Vadodara 390007. India

&nbsp;

&nbsp;

&nbsp;

&nbsp;&nbsp;

Annexure

&nbsp;

a.	Name of the target entity, details in brief such as size, turnover etc.	ICICI Prudential Asset Management Company (the Company) had total assets of ₹ 43.84 billion at March 31, 2025. Please see further details below:   Turnover (FY2025): ₹ 49.80 billion PAT (FY2025): ₹ 26.51 billion  
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”  	This transaction constitutes a related party transaction and it will be done at arms’ length. The Bank does not have any promoters.  
c.	Industry to which the entity being acquired belongs  	Financial and insurance services (Asset management company)
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Bank holds 51.0% of equity share capital of the Company. Subsequent to the proposed transaction there will not be any change in classification of the Company (i.e. it will continue to be a subsidiary of the Bank). This purchase will primarily be towards maintaining the Bank’s majority shareholding in the event of grant of stock-based compensation by the Company.  
e.	Brief details of any governmental or regulatory approvals required for the acquisition  	RBI approval is required
f.	Indicative time period for completion of the acquisition	The Bank will purchase additional shareholding in the Company, prior to the Company’s IPO  
g.	consideration - whether cash consideration or share swap or any other form and details of the same  	Cash consideration by purchase of equity shares from PCHL

&nbsp;

&nbsp;

&nbsp;

ICICI Bank Limited ICICI Bank Towers Bandra-Kurla Complex Mumbai 400 051, India. Tel.: 022- 4008 8900 Email:companysecretary@icicibank.com Website www.icicibank.com CIN.: L65190GJ1994PLC021012 Regd. Office: ICICI Bank Tower, Near Chakli Circle, Old Padra Road, Vadodara 390007. India

&nbsp;

&nbsp;

&nbsp;

&nbsp;&nbsp;

h.	Cost of acquisition and/or the price at which the shares are acquired  	To be decided at a subsequent time  
i.	Percentage of shareholding / control acquired and / or number of shares acquired  	The Bank proposes to purchase additional shareholding of up to 2% in the Company  
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	The Company is an asset management company managing significant assets under management in the mutual fund segment and rendering to portfolio management services for investors spread across the country and providing investment management services to alternative investment funds. The Company also provides advisory services to its clients across international markets. The Bank holds 51.0% and PCHL holds 49.0% in the Company.   Date of incorporation: June 22, 1993  History of last 3 years turnover (total revenue from operations + other income on a consolidated basis):  FY2025: ₹ 49.80 billion  FY2024: ₹ 37.61 billion   FY2023: ₹ 28.38 billion  Country of presence: India  

&nbsp;

Please take the above information on record.

&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;

ICICI Bank Limited ICICI Bank Towers Bandra-Kurla Complex Mumbai 400 051, India. Tel.: 022- 4008 8900 Email:companysecretary@icicibank.com Website www.icicibank.com CIN.: L65190GJ1994PLC021012 Regd. Office: ICICI Bank Tower, Near Chakli Circle, Old Padra Road, Vadodara 390007. India

&nbsp;

&nbsp;

&nbsp;

SIGNATURE

&nbsp;

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

&nbsp;

&nbsp;

&nbsp;

 	 	 		For ICICI Bank Limited
 		 
 		 
Date     :	July 9, 2025	By:	/s/ Prachiti Lalingkar
 	 	 	Name  :	Prachiti Lalingkar
 	 	 	Title    :	Company Secretary

&nbsp;&nbsp;

&nbsp;&nbsp;

ICICI Bank Limited ICICI Bank Towers Bandra-Kurla Complex Mumbai 400 051, India. Tel.: 022- 4008 8900 Email:companysecretary@icicibank.com Website www.icicibank.com CIN.: L65190GJ1994PLC021012 Regd. Office: ICICI Bank Tower, Near Chakli Circle, Old Padra Road, Vadodara 390007. India

&nbsp;

&nbsp;

FAQ

How many Nektar Therapeutics (NKTR) shares does Biotechnology Value Fund own?

The BVF entities collectively beneficially own 1,276,595 NKTR common shares.

What percentage of NKTR’s outstanding shares does BVF’s stake represent?

The filing states BVF’s aggregate stake equals 7.4% of the 17,301,061 shares outstanding as of 2 July 2025.

Is BVF’s filing activist or passive?

It is a Schedule 13G, indicating a passive investment with no intent to influence control.

Who signed the Schedule 13G on behalf of the BVF entities?

Mark N. Lampert signed as Authorized Signatory for all reporting persons.

Which BVF entities individually hold more than 5% of NKTR?

BVF GP Holdings LLC is deemed to hold 6.8%; Partners, BVF Inc. and Mr. Lampert each may be deemed to hold 7.4%.